Southeast Nebraska Cancer Center - 68th Street Place

Summary

Southeast Nebraska Cancer Center - 68th Street Place is a medical facility located in Lincoln, Nebraska. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Multiple Myeloma, Breast cancer and other specialties. Southeast Nebraska Cancer Center - 68th Street Place is involved with conducting 95 clinical trials across 159 conditions. There are 4 research doctors associated with this hospital, such as Ralph Hauke, MD, Joni A. Tilford, Mark J. Stavas, and Steve Dunder, MD.

Top PIs

Clinical Trials running at Southeast Nebraska Cancer Center - 68th Street Place

Lung Cancer

Prostate Cancer

Laryngeal Cancer

Breast Cancer

Non-Small Cell Lung Cancer

Oropharyngeal Carcinoma

Melanoma

Cutaneous Melanoma

Chronic Lymphocytic Leukemia

Squamous Cell Carcinoma

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria